Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC)

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Study Overview

• Status: Recruiting
• Conditions: Pancreatic Cancer; Liver Metastases; Pancreatic Neoplasm
• Intervention / Treatment: Diagnostic test: Preoperative MRI

Detailed Description

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jakob Kirkegård, MD, PhD; Phone Number: +4522900604; Email: jakob.kirkegaard@auh.rm.dk
• Study Contact Backup: Name: Frank Mortensen, MD, DMSc; Phone Number: +45222517296; Email: frmort@rm.dk

Study Locations

• Denmark
  • Aalborg, Denmark
    • Recruiting
    • Aalborg University Hospital
    • Contact: Mogens Stender, MD, PhD
  • Aarhus, Denmark, 8200
    • Recruiting
    • Aarhus University Hospital
    • Contact: Jakob Kirkegård, MD, PhD; Phone Number: +4522900604; Email: jakob.kirkegaard@auh.rm.dk
    • Contact: Frank V Mortensen, MD, DMSc; Phone Number: +45222517296; Email: frmort@rm.dk
    • Principal Investigator: Jakob Kirkegård, MD, PhD
    • Sub-Investigator: Frank V Mortensen, MD, DMSc
  • Copenhagen, Denmark
    • Recruiting
    • Rigshospitalet
    • Contact: Carsten P Hansen, MD, DMSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

• Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
• No liver metastases on CT
• At least 18 years old and able to provide informed consent
• Expected pancreatic ductal adenocarcinoma based on CT scan

Exclusion criteria:

• Metastatic disease
• Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
• Comorbidity rendering major surgery unfeasible (inoperable)
• No informed consent
• Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
• Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
• MRI with liver-specific contrast performed during standard workup.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Preoperative MRI; MRI before surgery.	Diagnostic test: Preoperative MRI; Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in treatment strategy	Change in treatment strategy from intended curative resection to other treatment based on MRI scan	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Liver metastases	Proportion of patients who had liver metastases detected on MRI	1 week
Surgery	Proportion of patients who made it to surgery/exploration	1 month
Resection	Proportion of patients in each arm who had a pancreatic resection performed	1 month
Intraoperatively detected liver metastases	Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.	1 month
Overall survival (1-year)	1-year overall survival.	1 year
Overall survival (3-year)	3-year overall survival.	3 years
Recurrence-free survival	Recurrence-free survival according to final treatment strategy.	3 years
Healthcare costs	Healthcare costs in patients with change of treatment.	3 years

Collaborators and Investigators

• Sponsor: University of Aarhus
• Collaborators: Rigshospitalet, Denmark; Aalborg University Hospital
• Investigators: Study Chair: Frank Mortensen, MD, DMSc, Aarhus University Hospital; Principal Investigator: Jakob Kirkegård, MD, PhD, Aarhus University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 30, 2022
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: June 16, 2022
• First Submitted That Met QC Criteria: June 16, 2022
• First Posted (Actual): June 23, 2022

Study Record Updates

• Last Update Posted (Actual): April 29, 2026
• Last Update Submitted That Met QC Criteria: April 28, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: magnetic resonance imaging
• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: MAGIPAC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Due to Danish law, no individual-level data can be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No